Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
종목 코드 GRAL
회사 이름Grail Inc
상장일Jun 12, 2024
설립일2020
CEOMr. Robert (Bob) Ragusa
직원 수1000
유형Ordinary Share
회계 연도 종료Jun 12
주소1525 O'brien Drive
도시MENLO PARK
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94025
전화18336942553
웹사이트https://grail.com/
종목 코드 GRAL
상장일Jun 12, 2024
설립일2020
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음